HOUSTON, TX (PRWEB) November 21, 2013
ReliantHeart, Inc., the manufacturer of the HeartAssist5® Ventricular Assist Device (VAD) has appointed to its Board of Directors Michael E. Gerber, writer of the best-selling book 'The E-Myth Revisited' and well-known legend of entrepreneurship.
INC. Magazine called Gerber “the World’s #1 Business Guru,” with his 40 years of experience addressing the needs of businesses owned primarily by people with technical skills but few business skills, and no place to go to get meaningful help. Over the years, Gerber’s companies have helped tens of thousands of business owners successfully transform their businesses into world-class operations.
Gerber created The Dreaming Room®, a training program that is held throughout the United States, Canada and the United Kingdom. Based on his experiences with entrepreneurs in these Dreaming Room events, along with the tens of thousands of clients Gerber has done business coaching with over the years, he authored 'Awakening the Entrepreneur Within.'
Gerber is also the best-selling author of 'The E-Myth Revisited,' co-authored several E-Myth industry-specific books, and 13 other business coaching books. The 'E-Myth Revisited,' has sold more than 5 million copies in 29 languages, and E-Myth methodology is taught in 118 universities worldwide.
According to Gerber, the core of the E-Myth is to work on the business, not in the business, in order to create the systems that allow ordinary people to produce extraordinary results, over and over again. The systems then allow the business to be continually improved through innovation, quantification and orchestration.
Gerber’s experience will contribute significantly to the ReliantHeart Board of Directors, as the company advances its revolutionary HeartAssist5® VAD, a powerful, implantable, electric pump designed to augment a failing human heart.
The HeartAssist5® has been proven effective in supporting blood circulation, reversing end-organ dysfunction and giving patients a much-improved quality of life as they await heart transplants. More than 12,000 patients worldwide have been supported by ventricular assist devices while awaiting transplant, however, the HeartAssist5® is the only VAD in the world that allows healthcare providers to monitor their patients remotely.
The HeartAssist5® System is currently being implanted in certified centers across Europe. ReliantHeart intends to enter a United States FDA approved clinical trial in 2014 to collect safety and effectiveness data. For more information, visit http://www.ReliantHeart.com.